NASDAQ:EXAS - EXACT Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$64.66 +0.90 (+1.41 %)
(As of 07/17/2018 08:00 AM ET)
Previous Close$63.76
Today's Range$63.65 - $64.93
52-Week Range$36.10 - $71.60
Volume898,600 shs
Average Volume2.43 million shs
Market Capitalization$7.77 billion
P/E RatioN/A
Dividend YieldN/A
EXACT Sciences logoExact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research


Debt-to-Equity Ratio0.71
Current Ratio15.30
Quick Ratio14.86


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$265.99 million
Price / Sales29.63
Cash FlowN/A
Price / CashN/A
Book Value$4.35 per share
Price / Book14.86


EPS (Most Recent Fiscal Year)($0.99)
Net Income$-114,390,000.00
Net Margins-38.61%
Return on Equity-20.92%
Return on Assets-15.73%


Outstanding Shares121,900,000
Market Cap$7,772.22

The Truth About Cryptocurrencies

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Thursday, April, 26th. The medical research company reported ($0.33) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.05. The medical research company earned $90.30 million during the quarter, compared to analysts' expectations of $86.31 million. EXACT Sciences had a negative net margin of 38.61% and a negative return on equity of 20.92%. The firm's revenue was up 86.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.32) EPS. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for EXACT Sciences.

What price target have analysts set for EXAS?

13 brokerages have issued 12 month target prices for EXACT Sciences' stock. Their predictions range from $41.00 to $85.00. On average, they expect EXACT Sciences' stock price to reach $63.1667 in the next year. This suggests that the stock has a possible downside of 2.3%. View Analyst Ratings for EXACT Sciences.

What is the consensus analysts' recommendation for EXACT Sciences?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (7/2/2018)
  • 2. BTIG Research analysts commented, "5 th , data on Exact Sciences’ second case control study for its liver biomarker is scheduled to be presented at the Digestive Disease Week (DDW) conference. Recall that the biomarkers are being co-developed with the Mayo Clinic. The abstract is available on DDW’s website and preliminary details show encouraging 95% sensitivity across all stages (93% specificity in healthy controls, 86% specificity in cirrhotic controls). A liver screening test is one of a number of platforms in EXAS’ cancer pipeline and given the improving traction here, may be the second real shot on the goal, though years away. While we don’t view this as a material stock-moving event, pipeline advancement is supportive of our positive thesis on the name. We reiterate our Buy rating and $70 PT." (6/5/2018)

Are investors shorting EXACT Sciences?

EXACT Sciences saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 11,792,911 shares, a decrease of 20.1% from the June 15th total of 14,757,507 shares. Based on an average daily volume of 3,612,076 shares, the days-to-cover ratio is currently 3.3 days. Currently, 9.9% of the shares of the company are short sold. View EXACT Sciences' Current Options Chain.

Who are some of EXACT Sciences' key competitors?

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 52)
  • Mr. Jeffrey T. Elliott CFA, CFO & Chief Accounting Officer (Age 40)
  • Mr. Maneesh K. Arora, Sr. VP, COO & Director (Age 49)
  • Dr. Graham P. Lidgard Ph.D., Chief Science Officer and Sr. VP of R&D (Age 69)
  • Mr. D. Scott Coward, Chief Legal Officer, Sr. VP, Gen. Counsel and Sec. (Age 53)

Has EXACT Sciences been receiving favorable news coverage?

Headlines about EXAS stock have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. EXACT Sciences earned a news sentiment score of 0.49 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 46.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include KAMES CAPITAL plc (0.64%), Thompson Investment Management Inc. (0.18%), Handelsbanken Fonder AB (0.17%), Columbia Partners L L C Investment Management (0.09%), Fisher Asset Management LLC (0.05%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which institutional investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Thompson Investment Management Inc., Columbia Partners L L C Investment Management and Handelsbanken Fonder AB. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

Which institutional investors are buying EXACT Sciences stock?

EXAS stock was acquired by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Fisher Asset Management LLC, Bank of Montreal Can, State of Alaska Department of Revenue, Gofen & Glossberg LLC IL, Orgel Wealth Management LLC, Crescent Grove Advisors LLC and Xact Kapitalforvaltning AB. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson, Katherine S Zanotti, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $64.66.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $7.77 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.

MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  622 (Vote Outperform)
Underperform Votes:  346 (Vote Underperform)
Total Votes:  968
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.